Clinician perspectives on current issues in lung cancer drug development Review uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Drugs, Investigational
  • Lung Neoplasms
  • Quinolines
  • Receptor, Epidermal Growth Factor

abstract

  • Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.

publication date

  • January 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5131641

Digital Object Identifier (DOI)

  • 10.1016/j.jtho.2016.05.009

PubMed ID

  • 27401214

Additional Document Info

start page

  • 1387

end page

  • 96

volume

  • 11

number

  • 9